Tretinoin
Also known as: Retin-A, Tretinoina, All-trans Retinoic Acid, ATRA
Retinoid | Skin Rejuvenation & Anti-Aging
Overview
Tretinoin is the gold standard topical retinoid for skin aging and acne, FDA-approved since 1971 for acne vulgaris and later for the treatment of photoaging (fine wrinkles, mottled hyperpigmentation, roughness). As the acid form of vitamin A, it is the most extensively studied topical anti-aging compound in dermatology, backed by decades of clinical evidence. Tretinoin accelerates epidermal cell turnover, stimulates collagen synthesis in the dermis, and improves the overall architecture of photodamaged skin. It has become a cornerstone of the biohacking and skincare optimization community due to its proven ability to reduce fine lines, even out skin tone, and improve skin texture with consistent long-term use.
Key benefits
- Reduces fine lines and wrinkles with consistent long-term use (strongest evidence of any topical)
- Stimulates new collagen synthesis (procollagen I and III) in photoaged skin
- Accelerates epidermal cell turnover, improving skin texture and smoothness
- Reduces mottled hyperpigmentation and evens skin tone
- FDA-approved treatment for acne vulgaris with over 50 years of clinical use
- Treats and prevents comedonal and inflammatory acne by normalizing follicular keratinization
- Enhances penetration and efficacy of other active skincare ingredients
Mechanism of action
Tretinoin binds to retinoic acid receptors (RARs) in the cell nucleus, specifically RAR-alpha, RAR-beta, and RAR-gamma, which form heterodimers with retinoid X receptors (RXRs). These activated receptor complexes bind to retinoic acid response elements (RAREs) in DNA, modulating the transcription of genes involved in cellular differentiation, proliferation, and apoptosis. In the epidermis, tretinoin accelerates keratinocyte turnover from the typical 28-day cycle to approximately 14-16 days, promoting the shedding of damaged surface cells and their replacement with newer, healthier cells. In the dermis, tretinoin stimulates fibroblast activity, increasing the production of procollagen I and III, fibronectin, and elastin. It also inhibits matrix metalloproteinases (MMPs) that degrade collagen, and promotes angiogenesis, improving dermal blood supply. The net result is thicker, more organized epidermis, increased dermal collagen density, and reduced fine wrinkling.
Molecular data
- Type
- Endogenous retinoid (vitamin A metabolite)
- Half-life
- 0.5-2 hours (topical, local skin metabolism)
Indications
What the research community uses this compound for, with self-reported effectiveness.
Skin Aging
Acne
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 0.025% cream | Every other night or 2-3 nights per week for 2-4 weeks, then nightly | — |
| — | 0.05% cream or gel | Once nightly | — |
| — | 0.1% cream or gel | Once nightly | — |
| — | 0.04% or 0.08% microsphere gel (Retin-A Micro) | Once nightly | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Peeling and flaking (retinoid dermatitis), especially in the first 2-6 weeks
- Erythema (redness) and skin irritation at the application site
- Dryness and tightness of the skin
- Increased photosensitivity (heightened susceptibility to sunburn)
- Initial acne purging (transient worsening of breakouts in weeks 2-6)
Rare side effects
- Severe contact dermatitis or allergic reaction
- Temporary hypo- or hyperpigmentation (more common in darker skin tones)
- Eczematous reaction in individuals with pre-existing eczema or atopic dermatitis
- Blistering or crusting (indicative of overuse or excessive concentration)
Contraindications
- Pregnancy and women planning to become pregnant (tretinoin is a known teratogen; oral retinoids cause severe birth defects, and while topical absorption is minimal, it is contraindicated as a precaution)
- Breastfeeding (safety not established for topical tretinoin during lactation)
- Known hypersensitivity to tretinoin, other retinoids, or any formulation excipients
- Active eczema, rosacea, or severely compromised skin barrier at the application site
- Concurrent use of other strong topical irritants without medical supervision (e.g., benzoyl peroxide at high concentrations on the same area at the same time)
References
Primary literature and clinical-trial data informing this entry.